Should men with mild erectile dysfunction be closely evaluated for cardiovascular diseases in the Korean population?

Figures & data

Table 1. Demographics, history of ED, and history of smoking.

	Udenafil mild ED	Udenafil except for mild ED	Udenafil database	p
N	70 (6.0%)	1098 (94.0%)	1168 (100%)
Demographics
Age (years)	53 ± 8 (28–71)	55 ± 8 (27–80)	55 ± 8 (27–80)	NS
Weight (kg)	71 ± 9 (53–99)	71 ± 9 (47–109)	71 ± 9 (47–109)	NS
Height (cm)	169 ± 5 (158–180)	169 ± 5 (130–186)	169 ± 5 (130–186)	NS
BMI (kg/m^2)	25 ± 2 (19–32)	25 ± 3 (17–37)	25 ± 3 (17–37)	NS
Obesity				NS
Underweight (BMI < 18.5)	0 (0)	5 (0.5%)	5 (0.4%)	–
Normal weight (BMI 18.5–24.9)	39 (55.7%)	623 (56.7%)	662 (56.7%)	NS
Overweight (BMI 25–29.9)	29 (41.4%)	432 (39.3%)	461 (39.5%)	NS
Obese (BMI ≥ 30)	2 (2.9%)	38 (3.5%)	40 (3.4%)	NS
Erectile dysfunction
Duration (year)	3.8 ± 3.3 (0–19)	4.3 ± 3.6 (0–25)	4.2 ± 3.6 (0–25)	0.025*
Etiology				NS
Mainly organic	34 (48.6%)	629 (57.3%)	663 (56.8%)	0.040*
Mainly psychogenic	8 (11.4%)	68 (6.2%)	76 (6.5%)	NS
Mixed	28 (40.0%)	401 (36.5%)	429 (36.8%)	NS
Smoking				NS
Never smoked	20 (28.6%)	339 (30.9%)	367 (31.4%)	NS
Smoker	19 (27.1%)	347 (31.6%)	358 (30.7%)	NS
Ex-smoker	31 (44.3%)	412 (37.5%)	443 (37.9%)	NS
Prior user of other PDE-5 inhibitors	56 (80.0%)	787 (71.7%)	843 (72.2%)	NS

BMI, body mass index; PDE, phosphodiesterase; ED, erectile dysfunction; NS, not significant.

All variables were reported as mean ± standard deviation (range) or N (%).

*p < 0.05.

Table 2. Prevalence of comorbidities.

	Udenafil mild ED	Udenafil except for mild ED (matched)	Udenafil except for mild ED	p	Odds ratio (95% CI)
N	70	70	1098
Diabetes mellitus	26 (37.1%)		627 (57.1%)	0.001*	2.3 (1.4–3.7)
Hypertension	18 (25.7%)		358 (32.6%)	NS
BPH/prostatitis	24 (34.3%)		334 (30.4%)	–
Benign prostatic hyperplasia	24 (34.3%)		304 (27.7%)	NS
Prostatitis			30 (2.7%)	–
Lipid disorder	9 (12.9%)		173 (15.8%)	NS
Hypercholesterolemia	9 (12.9%)		172 (15.7%)	NS
Hypertriglyceridemia			1 (0.1)	–
Gatrointestinal disorder	10 (14.3%)		137 (12.5%)	NS
Gastritis	6 (8.6%)		95 (8.7%)	NS
Gastrooesophageal reflux disease	4 (5.7%)		38 (3.5%)	NS
Duodenitis			2 (0.2%)	–
Irritable bowel syndrome			2 (0.2%)	–
Liver disorder	5 (7.1%)		158 (14.4%)	NS
Viral hepatitis	3 (4.3%)		64 (5.8%)	NS
Hepatic steatosis	2 (2.9%)		47 (4.3%)	NS
Hepatic cirrhosis			3 (0.3)	–
Hepatitis, others			16 (0.5)	–
Depression			4 (0.4)	–
Anxiety disorder			3 (0.3)	–

BPH, benign prostatic hyperplasia; GI, gastrointestinal; ED, erectile dysfunction; NS, not significant.

All variables were reported as N (%).

*p < 0.05.

Table 3. Concomitant medications used in patients with ED.

	Udenafil mild ED	Udenafil except for mild ED	Udenafil database	p	Odds ratio (95% CI)
N	70	1098	1168
Drugs used in diabetes	26 (37.1%)	627 (57.1%)	653 (55.9%)	0.001*	2.3 (1.4–3.7)
Agents acting on the renin-angiotensin system	12 (17.1%)	309 (28.1%)	321 (27.5%)	0.046*	1.9 (1.1–3.6)
Calcium channel blockers	16 (22.9%)	285 (26.0%)	301 (25.8%)	NS
Beta blocking agents	8 (11.4%)	104 (9.5%)	112 (9.6%)	NS
Diuretics	7 (10.0%)	63 (5.7%)	69 (5.9%)	NS
Antithrombotic agents	12 (17.1%)	285 (26.0%)	297 (25.4%)	NS
Drugs used in benign prostatic hyperplasia	20 (28.6%)	264 (24.0%)	284 (24.3%)	NS
Lipid modifying agents	9 (12.9%)	162 (14.8%)	171 (14.6%)	NS
Anti-acid medications	33 (47.1%)	255 (23.2%)	288 (24.7%)	<0.001*	0.4 (0.2–0.6)
Drugs for functional gastrointestinal disorders	9 (12.9%)	119 (10.8%)	128 (11.0%)	NS

ED, erectile dysfunction; NS, not significant.

All variables were reported as N (%).

*p < 0.05.